The $630,000 Rebuttal

An associate I supervise asked me recently why I keep insisting that access has to be designed into psychedelic care from the start, rather than patched in later once the model proves itself. I used to answer that question with theory: liberation psychology, the political economy of who gets new treatments first. Now I answer it by pointing at a statute.

The New Mexico medical psilocybin program, created by the Medical Psilocybin Act of 2025, is on track to see its first patients by the end of December 2026. Before it has treated a single person, the state has already done something no other jurisdiction in the country has done: appropriated public money, $630,000 of it, specifically to cover psilocybin treatment for people who can't afford it. Every other state model treats affordability as a problem to solve eventually. New Mexico wrote it into the budget as a launch condition.

Senate Bill 219, signed in April 2025, made New Mexico the first state to create psilocybin access through its legislature rather than a ballot initiative. That procedural detail matters more than it sounds. Ballot-initiative programs like Oregon's Measure 109 arrive as voter mandates that agencies then have to retrofit into health systems. A legislature-driven program is built inside the health system from day one, with the Department of Health running it and licensed healthcare providers at the center rather than the edges.

The design is explicitly medical:

• Qualifying conditions: treatment-resistant major depression, PTSD, substance use disorders, and end-of-life care, with the department able to approve additional conditions over time.
• Required structure: at minimum, one preparation session and one post-administration integration session, with treatment occurring at approved sites.
• Provider protection: the Act was written so licensed professionals can participate without putting their licenses in jeopardy, a fear that has kept many clinicians at arm's length from state programs elsewhere.

A Medical Psilocybin Advisory Board guides the rulemaking, and the Act requires its composition to include, among others, a member of an Indigenous group, a mental health equity advocate, and a veteran. Who sits at the design table is itself a design choice, and this table was specified in statute.

The Act gives the Department of Health until December 31, 2027 to have the program operational. The department isn't waiting. Dominick Zurlo, who directs the state's Center for Medical Cannabis and Psilocybin, told the advisory board the goal is "to be able to see the initial patients by the end of December of 2026," a full year ahead of the statutory deadline. The department has hired a program manager and is staffing up; the advisory board began meeting publicly in December 2025 and is reviewing draft operational procedures.

Worth saying plainly: an agency target is not a statutory guarantee. Rulemaking on facilitator qualifications, producer licensing, treatment protocols, and dosage standards is still in progress, and any of it could slip. But a state agency voluntarily accelerating a psychedelic program by a year, amid what its sponsors describe as high public interest, is not the regulatory posture this field is used to.

The 2026 legislative session appropriated $630,000 for the Medical Psilocybin Treatment Equity Fund, the first public money anywhere in the country earmarked to pay for psilocybin treatment for low-income patients. The same session sent $300,000 to the University of New Mexico for research on psychedelic-assisted therapy in end-of-life care.

Is $630,000 enough? Of course not. Psilocybin remains Schedule I federally, which means no insurance product, public or private, can cover this treatment; a fund that size will reach hundreds of patients, not thousands, against qualifying conditions that describe a far larger population. If the fund is judged as a budget line, it's modest.

Judge it instead as an argument. For years, the standard response to clinicians like me who raise affordability has been some version of "equity is a nice idea, but programs have to be financially viable first." Oregon ran that experiment: out-of-pocket pricing, no subsidy mechanism, and by early 2026 roughly a third of its licensed service centers had closed, even as early outcome data suggested the clients who could afford sessions were improving. The model didn't fail clinically. It failed economically, for exactly the people it was never designed to reach. New Mexico looked at that result and made the opposite opening move. The fund's existence concedes the point the industry keeps dodging: if you don't budget for access, you have decided who the program is for.

Honest ledger of open questions, because rulemaking is where design intentions go to be tested:

• Who can facilitate. The Act leaves provider qualifications and training standards to rulemaking. Which license types qualify, what training is required, and what it will cost are all undecided, and that last variable will determine whether the workforce reflects the equity intent.
• How the fund will actually work. Eligibility criteria and administration details haven't been published.
• Supply and settings. Producer licensing and approved-site requirements are still being drafted.

That training-cost question deserves the most scrutiny. If New Mexico imports the $8,000–$10,000 facilitator-training price structure that Oregon's market normalized, it will have built an equitable front door onto an inequitable workforce pipeline. The program's design says the state knows better. We'll see if the rules do.

Every state considering psilocybin access legislation for the next decade will have two reference cases: Oregon, where access was an afterthought and the market contracted, and New Mexico, where access was a launch condition. Clinicians get asked about this landscape constantly, and "it depends which state model wins the argument" is now an accurate answer. Watch three things between now and December: the facilitator qualification rules, the equity fund's eligibility criteria, and whether the launch date holds. Those three details will tell you whether the rebuttal held up in practice.

I'll be tracking New Mexico's rulemaking, the facilitator requirements, and the equity fund rollout as they're published. Join the newsletter below for the updates as they land.

It is a state medical program created by the 2025 Medical Psilocybin Act (Senate Bill 219), the first US psilocybin-access law passed through a legislature rather than a ballot initiative. The Department of Health runs it, with licensed healthcare providers central rather than at the edges. It is on track to see its first patients by the end of December 2026.

The Act names treatment-resistant major depression, PTSD, substance use disorders, and end-of-life care, and lets the Department of Health add conditions over time. Treatment must include at least one preparation session and one integration session at approved sites. The Act also protects participating licensed professionals from putting their licenses in jeopardy.

The statute requires the program operational by December 31, 2027, but the Department of Health is targeting first patients by the end of December 2026, a year early. That is an agency goal, not a guarantee: rulemaking on facilitator qualifications, producer licensing, treatment protocols, and dosage standards is still in progress and could slip.

New Mexico built access in from the start. It is legislature-driven and medical, with named qualifying conditions and provider protections, and it appropriated $630,000 to cover treatment for low-income patients before opening. Oregon left affordability to the market, with out-of-pocket pricing and no subsidy, and about a third of its service centers later closed.